Kane Biotech Announces Upcoming Webinar and Growth Plans for 2025
WINNIPEG, Manitoba — Kane Biotech Inc. (TSX-V: KNE; OTCQB: KNBIF) is thrilled to announce it will be hosting an informative webinar, allowing investors and stakeholders a glimpse into what the company has in store for 2025. The event is scheduled for Thursday at 4:15 PM Eastern Time, offering a unique opportunity to hear directly from the leadership team.
Registration and Key Speakers
Individuals interested in attending the event can easily register online. Marc Edwards, President and CEO, and Dr. Robert Huizinga, Executive Chairman, will highlight the expectations for the upcoming year, drawing upon the achievements and milestones reached over the past year.
Notable Milestones Achieved
The year 2024 was particularly significant for Kane Biotech, marked by several key milestones that set the stage for future growth:
- Completion of the scale-up manufacturing of revyve™ Antimicrobial Wound Gel Spray.
- Partnership with a new U.S. distribution partner for revyve™ Antimicrobial Wound Gel, increasing market reach.
- Health Canada Approval for revyve™, enabling expanded commercial activities in Canadian markets.
- Agreement to acquire FB Dermatology, aiming to bolster sales and presence across the EU, Australia, and New Zealand.
- Participation in a Multinational Corporate Collaboration project with a notable global wound care company under NRC-IRAP.
- Distribution agreements established with Razan Medical Trading in the UAE and Qatar Datamation Systems, facilitating sales in the GCC region.
- NRC-IRAP funding secured to support the growth and diversification of the revyve™ product family.
- FDA Approval granted to raise dosage allowance for the revyve™ Antimicrobial Wound Gel.
- Acquisition of ISO 13485:2016 MDSAP Quality Certification, paving the way for increased sales in new markets.
- Successful commercial sale of revyve™ Antimicrobial Wound Gel to ProgenaCare Global in Q3.
- Revenue boost from the $12.5 million USD sale of STEM Animal Health to Dechra Veterinary Products, underscoring the quality of Kane’s technology.
Marketing Enhancements Through Strategic Partnerships
Moreover, Kane has announced a six-month service agreement with Outside The Box Capital (OTBC), enhancing its marketing efforts to communicate vital information about the company to the financial community. These services will include digital marketing initiatives designed to increase visibility. The collaboration with OTBC reflects Kane’s commitment to raising awareness and attracting investor interest.
About Kane Biotech Inc.
Kane Biotech is a pioneering biotechnology firm dedicated to the research and commercialization of innovative technologies aimed at tackling microbial biofilms. With an extensive intellectual property portfolio, including 65 patents and continued research output, Kane is positioning itself at the forefront of its industry. Key products like DispersinB®, coactiv+™, and revyve™ are at the heart of its mission to improve health outcomes globally.
Contact Information
For further details or inquiries, reach out to:
- Marc Edwards
Chief Executive Officer
Email: medwards@kanebiotech.com - Ray Dupuis
Chief Financial Officer
Email: rdupuis@kanebiotech.com
Frequently Asked Questions
What is the purpose of the upcoming Kane Biotech webinar?
The webinar is designed to update investors on Kane Biotech's plans and achievements for 2025, highlighting significant milestones and company developments.
When is the Kane Biotech webinar scheduled?
The webinar is scheduled for Thursday at 4:15 PM Eastern Time.
Who are the key speakers during the webinar?
Key speakers for the webinar include Marc Edwards, the company's President and CEO, and Dr. Robert Huizinga, Executive Chairman.
What notable milestones did Kane Biotech achieve in 2024?
Kane Biotech achieved critical milestones, including FDA approval, new partnerships, and the acquisition of FB Dermatology, expanding its market presence.
How is Kane Biotech improving its visibility in the market?
Kane is engaged in a marketing agreement with Outside The Box Capital to utilize digital marketing strategies for better outreach and visibility to investors.
